Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Coronary Heart Disease | Original investigation

Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study

Authors: Hongjiang Wu, Eric S. H. Lau, Aimin Yang, Ronald C. W. Ma, Alice P. S. Kong, Elaine Chow, Wing-Yee So, Juliana C. N. Chan, Andrea O. Y. Luk

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

Nationwide studies on contemporary trends in incidence of diabetes-related complications in Asia are lacking. We describe trends in incident coronary heart disease (CHD), stroke, heart failure, hyperglycaemic crisis, and lower-extremity amputation (LEA) in people with diabetes in Hong Kong between 2001 and 2016.

Methods

The Hong Kong Diabetes Surveillance Database (HKDSD) is a territory-wide diabetes cohort identified from Hong Kong Hospital Authority electronic medical record system. We identified events of CHD, stroke, heart failure and hyperglycaemic crisis using hospital principal diagnosis codes at discharge and that of LEA using inpatient procedure codes. We used Joinpoint regression analysis to describe incidence trends by age and sex.

Results

Between 2001 and 2016, a total of 390,071 men and 380,007 women aged 20 years or older with diabetes were included in the HKDSD. Event rates of CHD, stroke, heart failure, hyperglycaemic crisis and LEA declined by 69.4% (average annual percent change: − 7.6, 95% CI − 10.2, − 5.0), 70.3% (− 8.7, 95% CI − 9.8, − 7.5), 63.6% (− 6.4, 95% CI − 8.0, − 4.7), 59.1% (− 6.6, 95% CI − 12.4, − 0.44), and 67.5% (− 5.8, 95% CI − 7.2, − 4.4), in men and by 77.5% (− 9.9, 95% CI − 11.8, − 7.9), 74.5% (− 9.0, 95% CI − 9.6, − 8.4), 65.8% (− 7.0, 95% CI − 8.0, − 6.0), 81.7% (− 8.5, 95% CI − 10.5, − 6.5), and 72.7% (− 9.1. 95% CI − 12.2, − 5.8) in women, respectively, over a 16-year period in people with diabetes in Hong Kong. Joinpoint analysis identified greater declines in event rates of the five diabetes-related complications in the earlier one-third of study period and slowed down but remained significant until 2016. Event rates decreased for all age groups above 45 years for both sexes. There was no significant change in event rates in the group aged 20–44 years except for decline in hyperglycaemic crisis.

Conclusions

The event rates of diabetes-related complications have declined substantially with no evidence of stabilization or increase in Hong Kong up to 2016. Improvements in outcome were observed for all age subgroups but not in young people with diabetes, calling for urgent action to improve quality of care to prevent complications in young people at risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019.
2.
go back to reference Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.CrossRef Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.CrossRef
3.
go back to reference Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.PubMedPubMedCentralCrossRef Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.PubMedPubMedCentralCrossRef
4.
go back to reference Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1):150.PubMedPubMedCentralCrossRef Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1):150.PubMedPubMedCentralCrossRef
5.
go back to reference Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRef Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRef
6.
go back to reference UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef
7.
go back to reference Davies MJ, DAlessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98.PubMedCrossRef Davies MJ, DAlessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98.PubMedCrossRef
8.
go back to reference Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–40.PubMedCrossRef Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–40.PubMedCrossRef
9.
go back to reference Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef
10.
go back to reference Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedPubMedCentralCrossRef Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedPubMedCentralCrossRef
11.
go back to reference Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.PubMedCrossRef Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.PubMedCrossRef
12.
go back to reference Wu H, Lau ESH, Ma RC, Kong APS, Wild SH, Goggins W, Chow E, So W-Y, Chan JCN, Luk AOY. Secular trends in all-cause and cuase-specific mortality in people with diabetes in Hong Kong, 2001–2016: a retrospective cohort study. Diabetologia. 2020;63(4):757–66.PubMedCrossRef Wu H, Lau ESH, Ma RC, Kong APS, Wild SH, Goggins W, Chow E, So W-Y, Chan JCN, Luk AOY. Secular trends in all-cause and cuase-specific mortality in people with diabetes in Hong Kong, 2001–2016: a retrospective cohort study. Diabetologia. 2020;63(4):757–66.PubMedCrossRef
13.
go back to reference Cheung N-T, Fung V, Wong WN, Tong A, Sek A, Greyling A, Tse N, Fung H. Principles-based medical informatics for success-How Hong Kong built one of the world’s largest integrated longitudinal electronic patient records. Stud Health Technol Inform. 2007;129(1):307.PubMed Cheung N-T, Fung V, Wong WN, Tong A, Sek A, Greyling A, Tse N, Fung H. Principles-based medical informatics for success-How Hong Kong built one of the world’s largest integrated longitudinal electronic patient records. Stud Health Technol Inform. 2007;129(1):307.PubMed
15.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.PubMedCrossRef Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.PubMedCrossRef
16.
go back to reference American Diabetes Association. 10 Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S103–23.CrossRef American Diabetes Association. 10 Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S103–23.CrossRef
17.
go back to reference Hsu C-Y, Chen Y-T, Su Y-W, Chang C-C, Huang P-H, Lin S-J. Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab. 2017;102(7):2373–81.PubMedCrossRef Hsu C-Y, Chen Y-T, Su Y-W, Chang C-C, Huang P-H, Lin S-J. Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab. 2017;102(7):2373–81.PubMedCrossRef
18.
go back to reference Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, Weng W, Bauman J, Ganguly R, Burguera B. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):54.PubMedPubMedCentralCrossRef Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, Weng W, Bauman J, Ganguly R, Burguera B. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):54.PubMedPubMedCentralCrossRef
19.
go back to reference Fei Y, Tsoi M-F, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18(1):112.PubMedPubMedCentralCrossRef Fei Y, Tsoi M-F, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18(1):112.PubMedPubMedCentralCrossRef
20.
go back to reference Ke C, Stukel TA, Luk A, Shah BR, Jha P, Lau E, Ma RC, So W-Y, Kong AP, Chow E. Development and validation of algorithms to classify type 1 and 2 diabetes according to age at diagnosis using electronic health records. BMC Med Res Methodol. 2020;20(1):1–15.CrossRef Ke C, Stukel TA, Luk A, Shah BR, Jha P, Lau E, Ma RC, So W-Y, Kong AP, Chow E. Development and validation of algorithms to classify type 1 and 2 diabetes according to age at diagnosis using electronic health records. BMC Med Res Methodol. 2020;20(1):1–15.CrossRef
21.
go back to reference Chan JCN, Lim L-L, Luk AOY, Ozaki R, Kong APS, Ma RCW, So W-Y, Lo S-V. From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions. Diabetes Care. 2019;42(11):2022–31.PubMedCrossRef Chan JCN, Lim L-L, Luk AOY, Ozaki R, Kong APS, Ma RCW, So W-Y, Lo S-V. From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions. Diabetes Care. 2019;42(11):2022–31.PubMedCrossRef
22.
go back to reference Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3–16.PubMedCrossRef Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3–16.PubMedCrossRef
23.
go back to reference Gregg EW, Hora I, Benoit SR. Resurgence in Diabetes-Related Complications. JAMA. 2019;321(19):1867–8.PubMedCrossRef Gregg EW, Hora I, Benoit SR. Resurgence in Diabetes-Related Complications. JAMA. 2019;321(19):1867–8.PubMedCrossRef
24.
go back to reference Liu C-C, Chen K-R, Chen H-F, Huang H-L, Ko M-C, Li C-Y. Trends in hospitalization for diabetic ketoacidosis in diabetic patients in Taiwan: analysis of national claims data, 1997–2005. J Formos Med Assoc. 2010;109(10):725–34.PubMedCrossRef Liu C-C, Chen K-R, Chen H-F, Huang H-L, Ko M-C, Li C-Y. Trends in hospitalization for diabetic ketoacidosis in diabetic patients in Taiwan: analysis of national claims data, 1997–2005. J Formos Med Assoc. 2010;109(10):725–34.PubMedCrossRef
25.
go back to reference Jung CH, Chung JO, Han K, Ko S-H, Ko KS, Park J-Y. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006–2013). Cardiovasc Diabetol. 2017;16(1):1.PubMedPubMedCentralCrossRef Jung CH, Chung JO, Han K, Ko S-H, Ko KS, Park J-Y. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006–2013). Cardiovasc Diabetol. 2017;16(1):1.PubMedPubMedCentralCrossRef
26.
go back to reference Kaewput W, Thongprayoon C, Mungthin M, Jindarat S, Varothai N, Suwannahitatorn P, Rangsin R, Mao MA, Cheungpasitporn W. Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: a nationwide study. J Evid Based Med. 2019;12(1):22–8.PubMedCrossRef Kaewput W, Thongprayoon C, Mungthin M, Jindarat S, Varothai N, Suwannahitatorn P, Rangsin R, Mao MA, Cheungpasitporn W. Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: a nationwide study. J Evid Based Med. 2019;12(1):22–8.PubMedCrossRef
27.
go back to reference Luk AO, Hui EM, Sin M, Yeung C, Chow W, Ho AY, Hung H, Kan E, Ng C, So W. Declining trends of cardiovascular-renal complications and mortality in type 2 diabetes: the Hong Kong Diabetes Database. Diabetes Care. 2017;40(7):928–35.PubMedCrossRef Luk AO, Hui EM, Sin M, Yeung C, Chow W, Ho AY, Hung H, Kan E, Ng C, So W. Declining trends of cardiovascular-renal complications and mortality in type 2 diabetes: the Hong Kong Diabetes Database. Diabetes Care. 2017;40(7):928–35.PubMedCrossRef
28.
go back to reference Wan EYF, Fung CSC, Jiao FF, Yu EYT, Chin WY, Fong DYT, Wong CKH, Chan AKC, Chan KHY, Kwok RLP. Five-year effectiveness of the multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health service uses—a population-based and propensity-matched cohort study. Diabetes Care. 2018;41(1):49–59.PubMedCrossRef Wan EYF, Fung CSC, Jiao FF, Yu EYT, Chin WY, Fong DYT, Wong CKH, Chan AKC, Chan KHY, Kwok RLP. Five-year effectiveness of the multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health service uses—a population-based and propensity-matched cohort study. Diabetes Care. 2018;41(1):49–59.PubMedCrossRef
29.
go back to reference Ko GT, So W, Tong PC, Le Coguiec F, Kerr D, Lyubomirsky G, Tamesis B, Wolthers T, Nan J, Chan J. From design to implementation-The Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program. BMC Med Inform Decis Mak. 2010;10(1):26.PubMedPubMedCentralCrossRef Ko GT, So W, Tong PC, Le Coguiec F, Kerr D, Lyubomirsky G, Tamesis B, Wolthers T, Nan J, Chan J. From design to implementation-The Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program. BMC Med Inform Decis Mak. 2010;10(1):26.PubMedPubMedCentralCrossRef
30.
go back to reference Collaboration Cholesterol Treatment Trialists’. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.CrossRef Collaboration Cholesterol Treatment Trialists’. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.CrossRef
33.
go back to reference Rawshani A, Svensson A-M, Zethelius B, Eliasson B, Rosengren A, Gudbjörnsdottir S. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern Med. 2016;176(8):1146–54.PubMedCrossRef Rawshani A, Svensson A-M, Zethelius B, Eliasson B, Rosengren A, Gudbjörnsdottir S. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern Med. 2016;176(8):1146–54.PubMedCrossRef
34.
go back to reference Wu H, Bragg F, Yang L, Du H, Guo Y, Jackson CA, Zhu S, Yu C, Luk AOY, Chan JCN, et al. Sex differences in the association between socioeconomic status and diabetes prevalence and incidence in China: cross-sectional and prospective studies of 0.5 million adults. Diabetologia. 2019;62(8):1420–9.PubMedPubMedCentralCrossRef Wu H, Bragg F, Yang L, Du H, Guo Y, Jackson CA, Zhu S, Yu C, Luk AOY, Chan JCN, et al. Sex differences in the association between socioeconomic status and diabetes prevalence and incidence in China: cross-sectional and prospective studies of 0.5 million adults. Diabetologia. 2019;62(8):1420–9.PubMedPubMedCentralCrossRef
35.
go back to reference Wu H, Lau ES, Kong AP, Ma RC, Ozaki R, Cheung KK, Chow E, Tsang CC, Lau KP, Hui EM, et al. Association between educational level and cardiovascular disease and all-cause mortality in patients with type 2 diabetes: a prospective study in the Joint Asia Diabetes Evaluation Program. Clin Epidemiol. 2018;10:1561–71.PubMedPubMedCentralCrossRef Wu H, Lau ES, Kong AP, Ma RC, Ozaki R, Cheung KK, Chow E, Tsang CC, Lau KP, Hui EM, et al. Association between educational level and cardiovascular disease and all-cause mortality in patients with type 2 diabetes: a prospective study in the Joint Asia Diabetes Evaluation Program. Clin Epidemiol. 2018;10:1561–71.PubMedPubMedCentralCrossRef
36.
go back to reference Li Y, Zou Y, Wang S, Li J, Jing X, Yang M, Wang L, Cao L, Yang X, Xu L. A pilot study of the FRAIL scale on predicting outcomes in Chinese elderly people with type 2 diabetes. J Am Med Dir Assoc. 2015;16(8):714.PubMedCrossRef Li Y, Zou Y, Wang S, Li J, Jing X, Yang M, Wang L, Cao L, Yang X, Xu L. A pilot study of the FRAIL scale on predicting outcomes in Chinese elderly people with type 2 diabetes. J Am Med Dir Assoc. 2015;16(8):714.PubMedCrossRef
37.
go back to reference Yeung RO, Zhang Y, Luk A, Yang W, Sobrepena L, Yoon K-H, Aravind S, Sheu W, Nguyen TK, Ozaki R. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2014;2(12):935–43.PubMedCrossRef Yeung RO, Zhang Y, Luk A, Yang W, Sobrepena L, Yoon K-H, Aravind S, Sheu W, Nguyen TK, Ozaki R. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2014;2(12):935–43.PubMedCrossRef
38.
go back to reference Ke C, Lau E, Shah BR, Stukel TA, Ma RC, So W-Y, Kong AP, Chow E, Clarke P, Goggins W. Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann Intern Med. 2019;170(3):145–54.PubMedCrossRef Ke C, Lau E, Shah BR, Stukel TA, Ma RC, So W-Y, Kong AP, Chow E, Clarke P, Goggins W. Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann Intern Med. 2019;170(3):145–54.PubMedCrossRef
39.
go back to reference Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–23.PubMedCrossRef Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–23.PubMedCrossRef
40.
go back to reference Luk AOY, Ke C, Lau ESH, Wu H, Goggins W, Ma RCW, Chow E, Kong APS, So W-Y, Chan JCN. Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study. Plos Med. 2020;17(2):e1003052.PubMedPubMedCentralCrossRef Luk AOY, Ke C, Lau ESH, Wu H, Goggins W, Ma RCW, Chow E, Kong APS, So W-Y, Chan JCN. Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study. Plos Med. 2020;17(2):e1003052.PubMedPubMedCentralCrossRef
Metadata
Title
Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study
Authors
Hongjiang Wu
Eric S. H. Lau
Aimin Yang
Ronald C. W. Ma
Alice P. S. Kong
Elaine Chow
Wing-Yee So
Juliana C. N. Chan
Andrea O. Y. Luk
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-020-01039-y

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.